Impact of
HNSCC
PFN2
TCGA
clustered
miR-1-3p
miR-133a-3p
miR-133b
miR-206
microRNA
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
12 Mar 2022
12 Mar 2022
Historique:
received:
17
02
2022
revised:
06
03
2022
accepted:
10
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Based on our original RNA sequence-based microRNA (miRNA) signatures of head and neck squamous cell carcinoma (HNSCC), it was revealed that the expression levels of miR-1-3p, miR-206, miR-133a-3p, and miR-133b were significantly suppressed in cancer specimens. Seed sequences of miR-1-3p/miR-206 and miR-133a-3p/miR-133b are identical. Interestingly, miR-1-3p/miR-133a-3p and miR-206/miR-133b are clustered in the human genome. We hypothesized that the genes coordinately controlled by these miRNAs are closely involved in the malignant transformation of HNSCC. Our in silico analysis identified a total of 28 genes that had putative miR-1-3p/miR-133a-3p and miR-206/miR-133b binding sites. Moreover, their expression levels were upregulated in HNSCC tissues. Multivariate Cox regression analyses showed that expression of PFN2 and PSEN1 were independent prognostic factors for patients with HNSCC (p < 0.05). Notably, four miRNAs (i.e., miR-1-3p, miR-206, miR-133a-3p, and miR-133b) directly bound the 3′untranslated region of PFN2 and controlled expression of the gene in HNSCC cells. Overexpression of PFN2 was confirmed in clinical specimens, and its aberrant expression facilitated cancer cell migration and invasion abilities. Our miRNA-based strategy continues to uncover novel genes closely involved in the oncogenesis of HNSCC.
Identifiants
pubmed: 35327465
pii: biomedicines10030663
doi: 10.3390/biomedicines10030663
pmc: PMC8944972
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : JSPS KAKENHI
ID : 19K09863
Organisme : JSPS KAKENHI
ID : 19K18759
Organisme : JSPS KAKENHI
ID : 21K09577
Références
Nat Commun. 2015 Sep 10;6:8230
pubmed: 26354229
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Br J Cancer. 2012 Jan 17;106(2):405-13
pubmed: 22068816
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Trends Cell Biol. 2004 Aug;14(8):461-9
pubmed: 15308213
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514295
Lancet Oncol. 2017 Mar;18(3):323-335
pubmed: 28131786
Cold Spring Harb Perspect Biol. 2018 Jan 2;10(1):
pubmed: 29295889
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
Cancer Sci. 2017 Aug;108(8):1681-1692
pubmed: 28612520
J Clin Oncol. 2021 Jun 10;39(17):1856-1864
pubmed: 33750196
Biol Rev Camb Philos Soc. 2018 Nov;93(4):1955-1986
pubmed: 29797774
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Int J Mol Sci. 2021 Jun 08;22(12):
pubmed: 34201353
Int J Mol Sci. 2021 Sep 13;22(18):
pubmed: 34576039
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Int J Oncol. 2015 Jul;47(1):325-34
pubmed: 25955017
Genome Res. 2009 Jan;19(1):92-105
pubmed: 18955434
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Br J Cancer. 2011 Mar 1;104(5):808-18
pubmed: 21304530
Cells. 2022 Jan 18;11(3):
pubmed: 35159126
Int J Oncol. 2019 Mar;54(3):1043-1052
pubmed: 30628646
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Int J Oncol. 2011 Nov;39(5):1099-107
pubmed: 21701775
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Int J Mol Sci. 2021 Sep 14;22(18):
pubmed: 34576110
Br J Cancer. 2014 Jul 15;111(2):386-94
pubmed: 24918822
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9781-9792
pubmed: 31799645
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Cancer Sci. 2013 Dec;104(12):1567-74
pubmed: 24033605
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Ann Oncol. 2012 Sep;23 Suppl 10:x173-7
pubmed: 22987957
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Int J Oncol. 2018 Jan;52(1):166-178
pubmed: 29115582
Cancers (Basel). 2021 Jun 04;13(11):
pubmed: 34199886
Front Immunol. 2022 Jan 18;12:807895
pubmed: 35116035
Biosci Rep. 2018 Jan 25;38(1):
pubmed: 29026005
Nucleic Acids Res. 2019 Sep 5;47(15):7753-7766
pubmed: 31340025
Wiley Interdiscip Rev RNA. 2020 Mar;11(2):e1563
pubmed: 31436881
J Transl Med. 2016 May 17;14(1):137
pubmed: 27188458
Mol Cancer. 2018 Oct 11;17(1):147
pubmed: 30309355
Oncol Rep. 2017 May;37(5):3146-3154
pubmed: 28405690
Auris Nasus Larynx. 2018 Aug;45(4):854-865
pubmed: 29233721
Oncotarget. 2012 Jan;3(1):9-21
pubmed: 22308266
Oncologist. 2010;15(9):994-1001
pubmed: 20798198
Nucleic Acids Res. 2009 May;37(8):2419-33
pubmed: 19295136
J Hum Genet. 2014 Feb;59(2):78-87
pubmed: 24284362
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Curr Opin Oncol. 2013 Jan;25(1):76-84
pubmed: 23197193
Breast Cancer. 2021 Mar;28(2):368-378
pubmed: 33047272
Nat Genet. 2006 Feb;38(2):228-33
pubmed: 16380711
Aging (Albany NY). 2020 Nov 21;12(24):25981-25999
pubmed: 33234737
Int J Oncol. 2016 Sep;49(3):1119-29
pubmed: 27573718
Int J Mol Sci. 2021 Nov 24;22(23):
pubmed: 34884487
Int J Biochem Cell Biol. 2010 Aug;42(8):1252-5
pubmed: 20619221
Elife. 2015 Aug 12;4:
pubmed: 26267216
Eur J Cancer. 2012 Apr;48(6):827-36
pubmed: 21745735